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Hematopoietic stem cells (HSCs) are rare cells that have the unique ability to self-renew and differentiate into cells
of all hematopoietic lineages. The expansion of HSCs has remained an important goal to develop advanced cell
therapies for bone marrow transplantation and many blood disorders. Over the last several decades, there have
been numerous attempts to expand HSCs in vitro using purified growth factors that are known to regulate HSCs.
However, these attempts have been met with limited success for clinical applications. New developments in the
HSC expansion field coupled with gene therapy and stem cell transplant should encourage progression in attractive
treatment options for many disorders including hematologic conditions, immunodeficiencies, and genetic disorders.
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Hematopoietic stem cells (HSCs) are rare stem cells that
have the ability to differentiate into specialized blood
cells, including lymphocytes, red blood cells, and plate-
lets [1]. While studies to successfully expand these cells
have spanned over the last three decades, a routine
method for ex vivo expansion of human HSCs is still
not available. However, stem cell biology has progressed
in recent years and thus ex vivo expansion of human
HSCs should become possible in the near future.
Stem cell transplants are a type of stem cell therapy used
to treat cancers such as lymphoma and leukemia and other
blood-related diseases [2]. Currently, there have been vari-
ous difficulties associated with ex vivo expansion methods
to generate stem cells for clinical therapies. The principle
goal of all ex vivo attempts to expand HSCs is to produce a
qualitative and quantitative acceptable cell population for
bone marrow transplantation. Earliest attempts at ex vivo
expansion centered on the use of cytokines known to sup-
port lineage committed cells [3]. Many researchers believe
that these factors also played a key role in HSC prolifera-
tion. Thus, researchers hypothesized that the addition or
removal of specific cytokines was able to regulate the
survival and expansion of the stem cell population [2,3]. In* Correspondence: jerell.aguila@stonybrook.edu
1Department of Pathology, The State University of New York at Stony Brook,
Stony Brook, NY 11794, USA
Full list of author information is available at the end of the article
© 2012 Schuster et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormore recent studies, researchers have focused on factors
critical for embryologic development and the importance of
signaling pathways that influence HSC self-renewal and ex-
pansion [2]. In the near future, it may be demonstrated that
the most comprehensive approach may be a combination
of various optimized conditions. Ex vivo expansion of HSCs
is crucial for their use in the treatment of malignant and
non-malignant diseases. Today, HSC gene therapy con-
tinues to be a highly attractive treatment option for many
disorders including hematologic conditions, immunodefi-
ciencies, and genetic disorders [2].
Umbilical cord blood vs. Peripheral blood stem
cells
In most bone marrow transplant centers, peripheral
blood stem cells (PBSCs) remain the preferred source of
stem cells for many types of allogeneic transplants, in
which matched related or unrelated donors are available
[3,4]. In the last decade, HSCs derived from umbilical
cord blood (UCB) have become more readily utilized for
allogeneic transplantation. Due to the low number of
recovered stem cells from UCB, the initial uses were
directed toward pediatric therapies [4]. With the assist-
ance of new technologies, UCB is now used as a new
source of stem cells for adult patients in numerous
transplant centers for the treatment of malignancies
such as leukemia, bone marrow failure states such as
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HSCs may provide a solution for patients who require a
potentially curative allogeneic transplant but lack a suit-
able adult donor [5].
The use of UCB is now standard practice in pediatrics
and, in fact, some pediatric hematologists are now advo-
cating the preferential use of UCB over peripheral blood
stem cells [6]. By utilizing multiple cord blood trans-
plants, UCB transplants have become an expanding
practice in adults for the treatment of malignant diseases
[6-8]. The advantages of UCB transplantation include
rapid availability, low risk of infection transmission,
absence of donor risk, and preservation of graft versus-
malignancy effects despite the relatively lower risk of
graft-versus-host disease (GVHD) because of more toler-
ance to HLA-mismatch [6,8]. The disadvantages of UCB
transplantation are the limited cell dose and resultant
delayed engraftment, as well as the lack of additional
immune cells if donor lymphocytes are needed [8]. In
addition, viral reactivation, with viruses such as CMV
and HHV6, has been noted to be problematic with these
transplants [7]. Finally, the nature of immune reconstitu-
tion following UCB transplants is yet another concern
that has been raised [8]. Recent advances have improved
results with UCB transplantation and outcomes with
matched unrelated transplants.
Advancements in the field of UCB transplantation
have moved attention from investigating its safety and
feasibility to addressing a myriad of specific issues. New
work in UCB transplantation has focused on extending
access, ensuring quality, accelerating engraftment, and
reviewing outcomes in specific subgroups of patients [8].
The major advance in extending this treatment modality
to adults has been the use of double cord blood trans-
plants [8]. Supported by a rapidly growing body of evi-
dence demonstrating the safety and efficacy of UCB
transplantation, this HSC source is now being used more
frequently for the treatment of adult patients with
hematologic malignancies [9]. After an initially limited
utilization among adults in contrast to routine utilization
in children who lack a suitable sibling donor, UCB trans-
plantation for older and larger patients is steadily in-
creasing and finding acceptance among adult transplant
physicians [9,10].
UCB is increasingly being used as an alternative source
of hematopoietic stem/progenitor cells (HSCs/HPCs) for
allogeneic bone marrow transplantation [9,10]. This is es-
pecially important for minority patients and patients of
mixed ethnicity. However, delayed engraftment remains a
significant problem, largely due to relatively low nucleated
cell doses available in single UCB units, particularly for
adults. Only a minority of adult patients has a UCB unit
with a "satisfactory" cell dose to meet the requirement for
allogeneic bone marrow transplantation [10,11]. Anumber of strategies are being investigated to overcome
the cell-dose barrier, including ex-vivo expansion of UCB
stem cells, intraosseous infusion of UCB cells, activating
homing receptors (such as CXCR4), and use of double
cord blood units [9-11]. To date, attempts at ex vivo ex-
pansion of hematopoietic stem cells have been met with
only limited success. To overcome the cell–dose barrier,
the combination of two UCB units is becoming common-
place in adolescent and adult populations [11]. The use of
multiple UCB has yielded many more UCB transplants to
treat adults, and this should be considered an important
advance in the field of UCB transplantation [9,10]. How-
ever, when two or more UCBs are transplanted into one
recipient, it is common for only one to be engrafted into
the patient [9-11]. The engrafting UCB unit cannot be
predetermined and molecular mechanisms surrounding
this finding are still unclear. In some studies, the use of
two UCB units appears to have a positive impact on out-
comes; however, delayed engraftment continues to pose a
significant risk for patients and increased GVHD is also
noted [9-11] . An additional disadvantage of using mul-
tiple units is substantial increases in costs compared to
the use of one UCB unit[11]. A possible way to improve
outcome and extend applicability of UCB transplantation
is via ex vivo or in vivo expansion and enhancement of
homing.
Ex vivo expansion of HSCs
In a publication in 2010, researchers described require-
ments which needed to be fulfilled when considering
in vitro expansion of HSCs: (1) HSCs must be able to
expand on a larger scale without sacrificing their self-
renewal ability; (2) Expansion of HSCs must be safe and
transplantable, and requires the method to be free of
feeder cells, serum proteins, or microbial agents [12]. In
order to determine optimal conditions for in vitro ex-
pansion of HSCs, investigators have adjusted various
parameters in the hopes of increasing the number of
engraftable stem cells. It is known that stem cells in the
bone marrow are found in niches created by non-stem
cells, and that these stem cells will remain undifferenti-
ated and appear immortal as long as they do not leave
the niche [5]. Therefore, the signaling pathways occur-
ring in this niche are important to understand and
examine. The manipulation of these signaling pathways
for genes such as Notch, HOX-B4, and Wnt [12,13] have
shown some positive results for ex vivo expansion.
Others have shown that overexpression of genes, such as
SALL4 [1] have the capacity to substantially increase the
number of HSCs/HPCs in vitro. A TAT-SALL4 fusion
protein (SALL4 protein fused with the TAT cell-
penetrating peptide) has also been shown to rapidly ex-
pand HSCs/HPCs, making it feasible to translate this
finding into the clinical setting [1]. Other experimental
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carbon receptors, chelators, stromal coculture, and
automated, continuous perfusion culture systems or
"bioreactors" [1].
Notch proteins are important for the survival, self-
renewal, and lineage determination of stem cells [12].
There are four Notch receptors (Notch1, Notch2,
Notch3, and Notch4), five ligands (Jagged-1, Jagged-2,
Delta-like-1, Delta-like-2, Delta-like-3, and Delta-like-4),
and several modifier proteins [13] that constitute the
Notch signaling network in vertebrates. A role for Notch
in hematopoiesis was initially described by detection of
the human Notch1 gene in CD34+ hematopoietic cells
[14]. It has been demonstrated that manipulating the
signaling pathway for the Notch gene plays a role in
HSC/HPC growth and expansion. Several studies have
found that this signaling network can augment HSCs/
HPCs in vitro and lead to a 100-fold increase in CD34+
precursors [12]. Numerous preclinical murine studies in-
volving Notch have been translated into human studies
utilizing an engineered Notch ligand for ex vivo gener-
ation of CD34+ cells [14]. In fact, the engineered Notch
ligand approach for ex vivo expansion is now under clin-
ical investigation. In this phase 1 clinical trial, patients
undergoing a myeloablative double cord blood trans-
plantation are receiving one non-manipulated cord
blood unit along with a second cord blood unit that has
undergone Notch-mediated ex vivo expansion [15]. Early
results show that patients may have better outcomes
who undergo these mixed-unit treatments; however,
long-term engraftment was still not achieved.
The homeobox gene family member HOXB4 has been
shown to be a regulator of hematopoietic differentiation
[16]. It is currently the most investigated transcription
factor for its potential to increase the self-renewal prop-
erties of HSCs. The HOXB4 gene has been demon-
strated to stimulate expansion of HSCs both in vivo and
in vitro while still allowing HSCs to differentiate for both
normal and myeloid cells [13]. In addition, overexpres-
sion through cellular modification of HOXB4 has led to
expansion of both murine and human hematopoietic
stem and progenitor cells. Human UCB CD34+ cells
treated with HOXB4 fusion proteins have resulted in a
2.5-fold increase in long-term repopulating cells com-
pared to uncultured controls [16]. Utilizing a more
stable form of this protein may prove to be one effective
strategy for ex vivo expansion in the future [16].
Wnt proteins are secreted morphogens that are essential
for basic developmental processes, such as progenitor-cell
proliferation, cell-fate specification, and the control of
asymmetric cell division in various tissues [17]. Wnt has
been found to stimulate in vitro expansion of HSCs/HPCs
[18]. Prostaglandin E2 (PGE2) is a multifunctional eicosa-
noid that has been shown to enhance the engraftingcapabilities of HSCs [19] by increasing both the homing
and self-renewal events of HSCs [20].
The transcription factor SALL4 is a member of the
SALL gene family and has been reported to play an es-
sential role in maintaining ES cell pluripotency through
interaction with Oct4 and Nanog [21,22] and establishes
a connection between ESCs and the self-renewal proper-
ties of HSCs [23,24]. Researchers have discovered that
overexpression of SALL4 can expand ex vivo human
mobilized HSCs from peripheral blood [1]. SALL4-
transduced cells were capable of ex vivo expansion of
both, CD34 +CD38- and CD34 +CD38+ cells and
showed enhanced stem cell engraftment and long term
repopulation capacity in NOD-SCID mice [1]. These
findings may suggest a possible new venue for investigat-
ing mechanisms of stem cell self-renewal and achieving
clinically significant expansion of human HSCs. How-
ever, further studies need to be performed in nonhuman
primates and human clinical studies to further test the
efficacy and safety of these methods, and to validate if
these expanded cells are capable of reconstituting
hematopoiesis in transplanted patients.
Current problems with ex vivo expansion
methods
Currently, there are various methods being utilized to
expand HSCs ex vivo. These include the use of cyto-
kine cocktails, copper chelators, exposure to signaling
molecules, stromal support and overexpression of
transcription factors [23]. To date, most advances
utilizing these various techniques are restricted to
murine models. While studies using human CD34+
cells transplanted into NOD/SCID mice have shown
some positive engraftment results [25], a large animal
model must still be tested to prove true long-term
multilineage engraftment. Many researchers believe
that transducing and expanding HSCs by using lenti-
viral vectors is the most promising tool for HSC-
based gene therapy [25]. Yet these studies must
clearly assess the risks of insertional mutagenesis be-
fore larger clinical trials can start. Furthermore, the
amount of time HSCs are expanded in culture is an
additional problem surrounding ex vivo expansion.
Increasing the period of culture promotes increased
cell division, which can also increase the likelihood of
spontaneous mutations or cytogenetic abnormalities
[25]. While success for transduced and expanded
HSCs has been demonstrated in NOD/SCID mice, it
will be extremely important for these studies to be
successfully translated into large animal or patient
studies that address safety and efficacy issues. Future
focus should be placed on the development of a
standardized clinical protocol to expand engraftable
long-term HSCs [26].
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Since 1999, there has been an average of about 100 new
gene therapy clinical trials annually pursuing treatments
for infectious diseases, cancer, and genetic diseases
[27,28]. Over this short period of time, new advance-
ments have occurred utilizing HSC expansion for gene
therapy. HSC gene therapy continues to be an attractive
therapeutic option for hematologic conditions, immune
diseases, and numerous genetic diseases. In addition,
HSCs may conceivably be the preeminent entry point
for gene therapy of hematopoietic and immune systems
because genetically modified HSCs are long-lived cells
that have the capability to transfer their therapeutic
characteristics to their daughter cells [13,28]. While
medical institutions worldwide are working on gene
therapy via HSCs, there are several formidable road-
blocks to successful outcomes.
Over the last decade, there have been positive results
obtained in gene therapy using HSCs in murine models,
but these achievements have not been able to be trans-
lated into successful outcomes in non-human primates
and human patients [27,28]. One possibility is that there
are fundamental differing mechanisms controlling
hematopoiesis in small short-lived and larger long-lived
animals [27,28]. Furthermore, the low efficiency of viral
transduction of HSCs in human trials may severely
decrease the level of chimerism or long-term repopulat-
ing ability of the cells [27].
HSCs from sources such as umbilical cord blood or
peripheral blood are rather limited. Transplant physi-
cians and researchers have recently shown much higher
interest in the usage of UCB cells for transplants due to
the advantages they hold over other sources. These in-
clude a non-invasive collection method, a high repopu-
lating efficiency, and a less stringent HLA-matching
requirement [28]. New studies have proposed that the
best alternative for successful transplants may be to
combine ex vivo expansion methods with genetic manip-
ulations of blood cells. Investigators believe that a
significant increase in safety and engraftment could be
achieved if genetically modified HSCs were expanded
while simultaneously screened for integration sites prior
to transplantation [28]. These gene modified HSCs could
be expanded with cytokines, signaling molecule expos-
ure, copper chelators, or overexpression of transcription
factors [23,28]. The most likely successful approach may
be one which involves a combination of methods.
Despite new advances in HSC gene therapy, the lack
of a proven gene-modified HSC drug or protocol
emphasizes that many obstacles remain inexplicable
[28]. The greatest challenge for in vivo studies may be
successfully achieving a safe level of gene dosage
coupled with an effective therapeutic level of gene-
modified HSCs [28]. Without new answers to thesecurrent challenges, the hope of safe HSC gene therapy
will be severely limited.
Epigenetics and HSCs
Epigenetic modifications play a key role in regulating cell
self-renewal and differentiation as well as tissue develop-
ment [29]. There are three main categories of modifica-
tions that can induce gene expression regulation which
include DNA methylation, histone modifications, and
nucleosome positioning [29]. New studies have shown
that epigenetic mechanisms, involving the regulation of
both gene expression and DNA recombination, usually
through the control of chromatin assembly, contribute
to establishing HSC unique properties [29-31]. To date,
the mechanisms involved in controlling the manner in
which genes are silenced or made accessible for tran-
scription in the hematopoietic system are still largely
unknown.
The most widely studied epigenetic modification in
humans is cytosine methylation [29]. The majority of the
time, DNA methylation occurs at regions called CpG
islands, or clusters of CpG dinucleotides of 0.5-2 kilo-
bases [29]. These sequences are usually constitutively
non-methylated in all animal cell types. The DNA
methyltransferases (DNMTs) are the enzymes respon-
sible for regulating the initiation and maintenance of the
methyl marks [29]. DNA methylation is a strong inhibi-
tor of gene expression which has a profound effect on
HSC characteristics. Histones and nucleosomes also play
a key role in regulating gene expression. Histone post-
transcriptional modifications occur predominantly in
histone tails. These modifications include phosphorylation,
acetylation, methylation, ubiquitination, ADP-ribosylation,
and SUMOylation [29-31]. Nucleosomes serve as barriers
to transcription by blocking access of transcription factors
and activators to their sites on DNA [29].
Recent studies have shown that the function of a
robust stimulator of HSCs/HPCs, SALL4, is associated
with epigenetic machinery [1,30]. SALL4 may provide
specific targets for histone deacetylase enzymes and
DNA methyltransferases resulting in the generation of
specific histone deacetylation or DNA methylation pat-
terns associated with HSC/HPC expansion [30].
Polycomb group (PcG) and Trithorax group (TrxG)
proteins have emerged as significant epigenetic regula-
tors. These groups act antagonistically to either promote
or repress transcription through regulation of specific
amino acid modifications in histones [29]. Polycomb
group proteins function in two main complexes in verte-
brates known as Polycomb Repressive Complex (PRC) 1
and PRC2 [31]. BMI1, a component of PRC1, has been
found to be a key factor in cell self-renewal [31]. BMI1
is expressed in HSCs and is retained within lymphoid
cells, but its expression decreases upon differentiation
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shown that overexpression of BMI1 in cord blood CD34
+ cells resulted in stem cell maintenance[32]. Finally,
after a culture period of 10 days, BMI1-overexpressing
cells display improved engraftment in NOD-SCID mice
[32].
Future promise of expansion of HSCs
While there are numerous clinical trials and assays
testing the efficacy and safety for a number of mole-
cules ability to expand HSCs, an ideal factor to in-
crease the number of HSCs in vitro without limiting
their in vivo regeneration capabilities has yet to be
found. The main difficulties surrounding HSC expan-
sion therapy include long-term engraftability and the
translation of in vitro observations into successful
in vivo outcomes. However, our increasing knowledge
base of the molecular mechanisms underlying the
function of HSCs within humans should shed light
upon what strategies may lead to the development of
an efficient gene therapy via HSCs. Advancements in
the methods used to expand HSCs should greatly im-
prove disease outcomes in the future. Further devel-
opments in the field coupled with gene therapy and
stem cell transplant should encourage progression in
cord blood transplantation, therapy for hematologic
diseases, and issues of efficacy and safety.
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